Yemaachi and Institut Pasteur Tunis Forge Oncogenetics Partnership to Sequence and Characterise Inflammatory Breast Cancer in Patients of African Descent
Partnership is emblematic of a global effort to characterise cancer development and progression in individuals of African descent, who have traditionally been excluded from genomic oncology studies and clinical trials 22nd October 2024, Tunis, Tunisia — Precision oncology company Yemaachi Biotech and Institut Pasteur Tunis today announced a research partnership investigating genomics in inflammatory breast […]